
Elicio refines its Phase III strategy for ELI-002 7P in pancreatic cancer
Elicio Therapeutics has reported that its Phase II AMPLIFY-7P study evaluating ELI-002 7P in patients with adjuvant mKRAS-driven pancreatic ductal adenocarcinoma (PDAC) did not meet its endpoint of disease-free survival (DFS). However, the company says landmark analyses during active ELI-002 7P treatment indicated early treatment benefit. Post-hoc… Read More













